A Phase IIb, Multicentre, Randomised, Double Blind, Placebo Controlled, Three-arm Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability at Week 24 of 2 Doses of CHF10067 (Zampilimab),in Participants With Idiopathic Pulmonary Fibrosis

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis (IPF). It is a phase IIb, multicentre, randomised, double-blind, placebo-controlled, three-arm parallel-group study. A total of 240 participants with IPF (Idiomatic Pulmonary Fibrosis) will be randomised in approximately 150 investigational sites in North and Latin America, Europe, Asia, and Oceania.

Eligibility

Age range

40+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  CHF10067

  Dose 1 CHF10067 Intravenous (IV) infusion

• Drug
  CHF10067

  Dose 2 CHF10067 IV infusion

• Other
  Placebo

  Placebo IV infusion

Locations (2)